NEW YORK (GenomeWeb) – Evotec announced today that it has acquired a non-exclusive license to CRISPR-Cas9 genome-editing technology from the Broad Institute and Harvard University.
Under the terms of the deal, Evotec may use the technology for its drug-development and R&D activities, including in the development of research tools and in target identification, as well as to strengthen its post-phenotypical screening target deconvolution platform.
Additional terms of the arrangement were not disclosed.
The Broad — a partnership between Harvard and the Massachusetts Institute of Technology — has issued a number of licenses to its CRISPR-Cas9 technology recently, including ones to ATCC, Transposagen, GE Healthcare, and Sigma-Aldrich.